Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials.
Silvetti Simona, Greco Teresa, Di Prima Ambra Licia, +6 more·Clinical research in cardiology : official journal of the German Cardiac Society
AIMS: Standard inotropic treatment is often necessary in end-stage heart failure but may be harmful. We performed a meta-analysis of randomized controlled trials to investigate the effect of repeated administration of levosimendan on survival in patients with chronic heart failure. METHODS AND RESULTS: Four investigat…